Research News and Research

RSS

Australian stem cell line offers fresh approach to diabetes cure

Australian researchers have developed the country’s first diabetes specific stem cell line, a major advance for patients suffering from the chronic disease.

21 Oct 2010

Lodestone Clinical Trials Supply Management solution achieves 'Powered By SAP Netweaver' certification

Lodestone Management Consultants today announced the new software release 1.0 of its Clinical Trials Supply Management (CTSM) Add-On Suite®. The solution has achieved SAP certification as powered by the SAP NetWeaver® technology platform, providing more transparency and a reduction of overages in the complex and time-consuming clinical development process of which the clinical supply chain is a key component.

21 Oct 2010

Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study

Results of a new international phase 4 study of patients with nosocomial pneumonia due to proven methicillin-resistant Staphylococcus aureus (MRSA) demonstrated that the antibiotic Zyvox® (linezolid) achieved a statistically significantly higher clinical success rate compared with vancomycin for the primary endpoint. The ZEPHyR (Linezolid in the treatment of subjects with nosocomial pneumonia proven to be due to methicillin-resistant Staphylococcus aureus) study was the largest ever conducted in this population.

21 Oct 2010

Bruker installs BioSpec 170/25 system at CEA NeuroSpin research center

Bruker announced today that it has successfully installed its BioSpec® 170/25 system at the CEA NeuroSpin research center near Paris, France. The world's first horizontal ultra-high magnetic field 17.2 Tesla MRI system features a magnet bore diameter of 25 cm. It is equipped with a novel Bruker BGA-S™ gradient system with unsurpassed amplitude and slew rate specifications for cutting-edge preclinical in vivo imaging on small animals.

21 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

Kensey Nash 2011 first quarter decreases 14% to $17.0 million

Kensey Nash Corporation , a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its first quarter ended September 30, 2010.

21 Oct 2010

First Edition: October 21, 2010

Today's headlines include news about how opponents of the health law are steering the educational efforts that surround it, as well as poll results that suggest continued Republican inroads at the polls.

21 Oct 2010

North Carolina Academic Center to conduct youth violence prevention research

North Carolina will be home to the nation's first rurally focused youth violence prevention center, with a federal grant worth nearly $6.5 million to support a new project based in Robeson County and led by University of North Carolina at Chapel Hill researchers.

21 Oct 2010

Cord Blood to explain queries on VoiceAmerica Radio Network

Cord Blood America, Inc. the umbilical cord blood stem cell preservation company focused on bringing the life-saving potential of stem cells to families nationwide and internationally, is pleased to announce that Chairman, CEO and co-founder Matthew Schissler and Dr. Geoffrey O'Neill, Vice President, Operations, will appear for one hour live on "Go Rogue & Get Rich" on The VoiceAmerica Radio Network.

21 Oct 2010

Cerenis raises €10 million in second close of Series C financing

Cerenis Therapeutics, a biopharmaceutical company specializing in the research and development of novel therapies based on HDL to treat cardiovascular and other metabolic diseases, announced today it has raised a further €10 million in a second close of its Series C financing. This takes the total funds raised in the Series C to €50 million and the total equity investment raised to date by the Company to €117 million.

21 Oct 2010

Alexion 2010 third quarter revenue increases from $102.6 to $141.6 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and nine months ended September 30, 2010.

21 Oct 2010

Venn Life Sciences acquires French CRO

Venn Life Sciences a multinational Clinical Research Organisation (CRO) announced today that it has acquired French CRO, DCI.

21 Oct 2010

Study finds online activities does not effect long-term psychological health

After the campus shootings at Virginia Tech in 2007 and Northern Illinois University in 2008, hundreds of affected students turned to social media websites to share their grief and search for solace. A new study of these students found that their online activities neither helped nor harmed their long-term psychological health.

21 Oct 2010

ISCTM to develop solutions for CNS clinical trial methodology

The International Society for CNS Clinical Trials and Methodology (ISCTM) met recently to develop solutions to challenges facing CNS clinical trial methodology.

21 Oct 2010

NBER project identifies and analyzes African successes

Conventional wisdom has long been negative on Africa. Historically, it has been seen as a failing continent, plagued by deep-rooted problems - poverty, corruption, war, and disease. But after four decades of relative stagnation, Africa has been growing rapidly. Since the 1990s, many African countries have seen economic and political improvements, more transparent elections, increased democracy and freedom of press. But these successes are not well understood.

21 Oct 2010

Major companies phase out BPA from food and beverage packaging

Major brand name companies including Hain Celestial, H.J. Heinz, ConAgra, and General Mills are taking a leadership role in responding to consumer market shifts as awareness about health hazards of the endocrine disrupting chemical bisphenol A (BPA) in food can linings rises.

21 Oct 2010

Highlights of Frontiers in Optics 2010/Laser Science XXVI Meeting

Scientists and engineers from around the world will gather on the shores of Lake Ontario in Rochester, N.Y. next week to discuss some of the latest breakthroughs in lasers and optics and their applications to cutting-edge science, the development of new materials, and medicine.

21 Oct 2010

Research identifies key regulators that control transmission of malaria parasite

Scientists at The University of Nottingham and the Wellcome Trust Sanger Institute near Cambridge have pin-pointed the 72 molecular switches that control the three key stages in the life cycle of the malaria parasite and have discovered that over a third of these switches can be disrupted in some way.

21 Oct 2010

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.

21 Oct 2010

Thomson Reuters Consumer Healthcare Sentiment Index rises for second month

Americans' confidence in their ability to obtain and afford healthcare rose for the second consecutive month in September, reversing a downward trend that had prevailed in the first half of the year, according to a consumer sentiment index produced by Thomson Reuters.

21 Oct 2010